| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Vx-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age · 2023 | Their institution | $126,969 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older · 2025 | Their institution | $100,907 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of Vx-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and A Cftr Genotype Not Responsive To Cftr Modulator Therapy · 2023 | Their institution | $71,763 |
| Vertex Pharmaceuticals Incorporated · A Study Evaluating the Long-Term Safety of Vx-445 Combination Therapy · 2020 | Their institution | $67,140 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Vx-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age · 2025 | Their institution | $66,948 |
| VERTEX PHARMACEUTICALS INCORPORATED · Evaluation of Elx/Tez/Iva in Cystic Fibrosis (Cf) Subjects 2 Through 5 Years · 2021 | Their institution | $59,211 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older · 2024 | Their institution | $58,801 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of Vx-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and A Cftr Genotype Not Responsive To Cftr Modulator Therapy · 2024 | Their institution | $56,322 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Open-Label Study Evaluating the Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older · 2024 | Their institution | $47,222 |
| Vertex Pharmaceuticals Incorporated · Study Evaluating the Long-Term Safety and Efficacy of Vx-445 Combination Therapy · 2020 | Their institution | $46,855 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Open-Label Study Evaluating the Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older · 2022 | Their institution | $41,412 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have A Cftr Gating Mutation · 2024 | Their institution | $39,712 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study Evaluating the Long Term Safety and Efficacy of Vx-659 Combination Therapy · 2019 | Their institution | $35,591 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-Cftr Mutation · 2019 | Their institution | $31,842 |
| Vertex Pharmaceuticals Incorporated · A Phase 3 Study of Vx-445 Combination Therapy in Cystic Fibrosis (Cf) Subjects Heterozygous for F508del and A Gating Or Residual Function Mutation (F/G and F/Rf Genotypes) · 2020 | Their institution | $31,093 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Study of Vx-445 Combination Therapy in Cystic Fibrosis (Cf) Subjects Heterozygous for F508del and A Gating Or Residual Function Mutation (F/G and F/Rf Genotypes) · 2019 | Their institution | $29,836 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Open-Label Study Evaluating the Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older · 2023 | Their institution | $28,693 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Open-Label Study Evaluating the Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older · 2025 | Their institution | $28,597 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have A Cftr Gating Mutation · 2019 | Their institution | $27,148 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have A Cftr Gating Mutation · 2019 | Their institution | $27,054 |
| Vertex Pharmaceuticals Incorporated · A Study To Evaluate the Safety and Efficacy of Long Term Treatment With Vx-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have An F508del-Cftr Mutation · 2020 | Their institution | $26,411 |
| VERTEX PHARMACEUTICALS INCORPORATED · Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 To Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del · 2019 | Their institution | $25,112 |
| Vertex Pharmaceuticals Incorporated · Long-Term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 To <24 Months of Age at Treatment Initiation · 2020 | Their institution | $24,125 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study Evaluating the Long-Term Safety of Vx-445 Combination Therapy · 2021 | Their institution | $22,897 |
| VERTEX PHARMACEUTICALS INCORPORATED · Evaluation of Elx/Tez/Iva in Cystic Fibrosis (Cf) Subjects 2 Through 5 Years · 2022 | Their institution | $22,881 |
| Vertex Pharmaceuticals Incorporated · A Study Evaluating the Long Term Safety and Efficacy of Vx-659 Combination Therapy · 2020 | Their institution | $22,087 |
| Genentech, Inc. · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2025 | Their institution | $21,607 |
| AstraZeneca UK Limited · A Randomized, Double-Blind, Two-Way Crossover Study To Assess the Effect of Hydrofluoroolefin (Hfo) Propellant Metered Dose Inhaler (Mdi) on Mucociliary Clearance Compared With Hydrofluoroalkane (Hfa) Propellant Mdi in Healthy Participants · 2024 | Their institution | $21,569 |
| Vertex Pharmaceuticals Incorporated · A Study To Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have A Cftr Gating Mutation · 2020 | Their institution | $21,173 |
| Insmed, Inc. · A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study To Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis · 2022 | Their institution | $18,572 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Study of Vx-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and A Minimal Function Mutation (F/Mf) · 2019 | Their institution | $16,443 |
| VERTEX PHARMACEUTICALS INCORPORATED · Study Evaluating the Long-Term Safety and Efficacy of Vx-445 Combination Therapy · 2021 | Their institution | $16,295 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study Evaluating the Long-Term Safety of Vx-445 Combination Therapy · 2022 | Their institution | $13,166 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With Cf, Homozygous for the F508del-Cftr Mutation · 2019 | Their institution | $12,482 |
| VERTEX PHARMACEUTICALS INCORPORATED · Clearing Lungs With Enac Inhibition in Primary Ciliary Dyskinesia · 2019 | Their institution | $12,358 |
| VERTEX PHARMACEUTICALS INCORPORATED · Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 To Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del · 2022 | Their institution | $10,880 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older · 2023 | Their institution | $10,322 |
| Vertex Pharmaceuticals Incorporated · A Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have A Cftr Gating Mutation · 2020 | Their institution | $10,291 |
| Vertex Pharmaceuticals Incorporated · A Phase 3 Study To Evaluate the Efficacy and Safety of Ivacaftor and Vx-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-Cftr Mutation · 2020 | Their institution | $10,240 |
| VERTEX PHARMACEUTICALS INCORPORATED · Study Evaluating the Long-Term Safety and Efficacy of Vx-445 Combination Therapy · 2022 | Their institution | $9,812 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study Evaluating the Long-Term Safety of Vx-445 Combination Therapy · 2019 | Their institution | $7,642 |
| VERTEX PHARMACEUTICALS INCORPORATED · Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis · 2019 | Their institution | $5,792 |
| Vertex Pharmaceuticals Incorporated · A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-Cftr Mutation · 2020 | Their institution | $5,692 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Vx-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age · 2024 | Their institution | $5,684 |
| Insmed, Inc. · A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study To Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis · 2023 | Their institution | $5,020 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have A Cftr Gating Mutation · 2023 | Their institution | $4,660 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of Vx-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and A Cftr Genotype Not Responsive To Cftr Modulator Therapy · 2025 | Their institution | $4,395 |
| VERTEX PHARMACEUTICALS INCORPORATED · Study Evaluating the Long-Term Safety and Efficacy of Vx-445 Combination Therapy · 2023 | Their institution | $4,032 |
| VERTEX PHARMACEUTICALS INCORPORATED · Evaluation of Elx/Tez/Iva in Cystic Fibrosis (Cf) Subjects 2 Through 5 Years · 2023 | Their institution | $3,648 |
| VERTEX PHARMACEUTICALS INCORPORATED · Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 To Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del · 2021 | Their institution | $3,026 |
| VERTEX PHARMACEUTICALS INCORPORATED · Long-Term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 To <24 Months of Age at Treatment Initiation · 2021 | Their institution | $2,816 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3 Study of Vx-445 Combination Therapy in Cystic Fibrosis (Cf) Subjects Heterozygous for F508del and A Gating Or Residual Function Mutation (F/G and F/Rf Genotypes) · 2021 | Their institution | $2,816 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study Evaluating the Long-Term Safety of Vx-445 Combination Therapy · 2023 | Their institution | $2,816 |
| VERTEX PHARMACEUTICALS INCORPORATED · Rollover Study To Evaluate the Safety and Efficacy of Long-Term Treatment With Lumacaftor in Combination With Ivacaftor · 2019 | Their institution | $2,617 |
| Vertex Pharmaceuticals Incorporated · A Phase 3 Study of Vx-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and A Minimal Function Mutation (F/Mf) · 2020 | Their institution | $2,560 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have A Cftr Gating Mutation · 2021 | Their institution | $2,468 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study Evaluating the Long Term Safety and Efficacy of Vx-659 Combination Therapy · 2022 | Their institution | $2,304 |
| Allergan, Inc. · Long-Term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements To Assess Any Narrowing of the Large Intestines Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy) · 2020 | Their institution | $2,218 |
| Allergan Inc. · Long-Term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements To Assess Any Narrowing of the Large Intestines Causing Adverse Intestinal Symptoms Fibrosing Colonopathy · 2019 | Their institution | $1,175 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Vx-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis · 2019 | Their institution | $1,097 |
| AbbVie Inc. · Creon · 2020 | Their institution | $1,043 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have A Cftr Gating Mutation · 2022 | Their institution | $900 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety and Efficacy of Long Term Treatment With Vx-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have An F508del-Cftr Mutation · 2019 | Their institution | $780 |
| Vertex Pharmaceuticals Incorporated · Evaluation of Elx/Tez/Iva in Cystic Fibrosis (Cf) Subjects 2 Through 5 Years · 2020 | Their institution | $747 |
| Vertex Pharmaceuticals Incorporated · Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 To Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del · 2020 | Their institution | $715 |
| AstraZeneca UK Limited · A Phase II Randomized Multi Center Double Blind Global Study To Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy As Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer Orion · 2025 | Their institution | $690 |
| VIVUS, Inc. · Long-Term Study in US Cystic Fibrosis · 2020 | Their institution | $608 |
| AbbVie, Inc. · Creon · 2019 | Their institution | $552 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study Evaluating the Long Term Safety and Efficacy of Vx-659 Combination Therapy · 2021 | Their institution | $512 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have A Cftr Gating Mutation · 2023 | Their institution | $461 |
| VIVUS, Inc. · Long-Term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements To Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms · 2019 | Their institution | $303 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have A Cftr Gating Mutation · 2021 | Their institution | $0 |